A Review of Osteoporosis in the Older Adult: An Update

被引：63
作者：
Alejandro, Paloma [1 ]
Constantinescu, Florina [1 ]
机构：
[1] Georgetown Univ, Med Ctr, MedStar Washington Hosp Ctr, Div Rheumatol, 110 Irving St Northwest 2A-66, Washington, DC 20010 USA
来源：
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2018年 / 44卷 / 03期
关键词：
Osteoporosis; Bisphosphonates; FRAX; Drug holiday; Hip fractures; Elderly; DXA; BONE-MINERAL DENSITY; ZOLEDRONIC ACID TREATMENT; POSTMENOPAUSAL WOMEN; PARATHYROID-HORMONE; FRACTURE RISK; VERTEBRAL FRACTURES; RANDOMIZED-TRIAL; ORAL IBANDRONATE; HIP FRACTURE; MEN;
D O I：
10.1016/j.rdc.2018.03.004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Osteoporosis in the elderly population is common. It results in more than 1.5 million fractures per year in the United States. The goal of managing osteoporosis is to prevent fractures. In men, osteoporosis is underrecognized and undertreated. More men than women die every year as a consequence of hip fractures. Bisphosphonates are the first-line treatment of men and women. In the past several years, advances in bone biology have resulted in major therapeutic advances. This article reviews the diagnosis and treatment of osteoporosis.
引用
收藏
页码：437 / +
页数：16
相关论文
共 70 条
[1]  
ABBASI AA, 1995, AM J MED SCI, V310, P229
[2]   Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone [J].
Amory, JK ;
Watts, NB ;
Easley, KA ;
Sutton, PR ;
Anawalt, BD ;
Matsumoto, AM ;
Bremner, WJ ;
Tenover, JL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) :503-510
[3]  
[Anonymous], REC DXA MAN FRAX IMP
[4]   Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy The FLEX Study [J].
Bauer, Douglas C. ;
Schwartz, Ann ;
Palermo, Lisa ;
Cauley, Jane ;
Hochberg, Marc ;
Santora, Art ;
Cummings, Steven R. ;
Black, Dennis M. .
JAMA INTERNAL MEDICINE, 2014, 174 (07) :1126-1134
[5]   Long-term effect of testosterone therapy on bone mineral density in hypogonadal men [J].
Behre, HM ;
Kliesch, S ;
Leifke, E ;
Link, TM ;
Nieschlag, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (08) :2386-2390
[6]   Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].
Black, Dennis M. ;
Delmas, Pierre D. ;
Eastell, Richard ;
Reid, Ian R. ;
Boonen, Steven ;
Cauley, Jane A. ;
Cosman, Felicia ;
Lakatos, Peter ;
Leung, Ping Chung ;
Man, Zulema ;
Mautalen, Carlos ;
Mesenbrink, Peter ;
Hu, Huilin ;
Caminis, John ;
Tong, Karen ;
Rosario-Jansen, Theresa ;
Krasnow, Joel ;
Hue, Trisha F. ;
Sellmeyer, Deborah ;
Eriksen, Erik Fink ;
Cummings, Steven R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822
[7]  
Black DM, 2016, NEW ENGL J MED, V374, P2096, DOI 10.1056/NEJMc1602599
[8]   The Effect of 6 Versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT) [J].
Black, Dennis M. ;
Reid, Ian R. ;
Cauley, Jane A. ;
Cosman, Felicia ;
Leung, Ping Chung ;
Lakatos, Peter ;
Lippuner, Kurt ;
Cummings, Steven R. ;
Hue, Trisha F. ;
Mukhopadhyay, Amitava ;
Tan, Monique ;
Aftring, R. Paul ;
Eastell, Richard .
JOURNAL OF BONE AND MINERAL RESEARCH, 2015, 30 (05) :934-944
[9]   Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long? [J].
Black, Dennis M. ;
Bauer, Douglas C. ;
Schwartz, Ann V. ;
Cummings, Steven R. ;
Rosen, Clifford J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (22) :2051-2053
[10]   The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) [J].
Black, Dennis M. ;
Reid, Ian R. ;
Boonen, Steven ;
Bucci-Rechtweg, Christina ;
Cauley, Jane A. ;
Cosman, Felicia ;
Cummings, Steven R. ;
Hue, Trisha F. ;
Lippuner, Kurt ;
Lakatos, Peter ;
Leung, Ping Chung ;
Man, Zulema ;
Martinez, Ruvie Lou Maria ;
Tan, Monique ;
Ruzycky, Mary Ellen ;
Su, Guoqin ;
Eastell, Richard .
JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (02) :243-254
1234567